Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.
about
Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinomaEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) CohortSkin cancer in organ transplant recipients: more than the immune system.Pathogenesis of nonmelanoma skin cancers in organ transplant recipientsA randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.Efficacy and comparative effectiveness of sirolimus as an anticancer drug.A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.p53 and rapamycin are additive.Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation.Skin cancer in transplant recipients, out of the woods. Scientific retreat of the ITSCC and SCOPE.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesDevelopments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.Skin changes following organ transplantation: an interdisciplinary challenge.Everolimus: efficacy and safety in cardiac transplantation.End-stage renal disease in 2010: Innovative approaches to improve outcomes in transplantation.Post-transplant malignancy: reducing the risk in kidney transplant recipients.Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients.An evaluation of sirolimus in renal transplantation.A drug safety evaluation of everolimus in kidney transplantation.Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.Immunostimulatory activity of lifespan-extending agents.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?Therapeutic targeting of Toll-like receptors in cutaneous disorders.Renal cancer in kidney transplanted patients.Transplantation of kidneys with tumors.Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review.The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling.Skin Cancers in Organ Transplant Recipients.Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases.Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinomaNew issues in heart transplantation for heart failure.Renal transplantation with kidneys affected by tumoursRenal association clinical practice guideline in post-operative care in the kidney transplant recipient
P2860
Q26851436-9C8568F2-C743-41AA-BE3D-BD6B7732D5B1Q28387851-95589206-E745-4260-B7B5-CE50CD2356A1Q30871643-754113B2-394B-4AFA-A984-594B4C13C6B6Q33880261-6EF9191D-38E3-4E2F-8C9E-21616A4965BFQ33923227-8263C354-87FC-4C27-8E12-EBBA96AB84A3Q34713840-B7422DF5-492C-401C-9C1A-93E33DA9036FQ34796915-05EC45FD-C626-4BFE-887A-29E6A6F721B2Q34891527-A46E3BE8-DA71-42FB-A473-3C61CAD61A74Q35805955-54D5E138-3340-4FCB-AEAB-0DC725A533ABQ36051817-20D9328C-BA04-40EC-AEA2-63EA9E250730Q36140629-D33DC915-CF86-4B82-8C72-3E592A90DE32Q36752004-79A113BD-ECAD-41D4-8E31-49A5439D376CQ37053236-7FCD46F3-6AC5-4443-B6BA-382698761F4DQ37132788-7C25BCE9-8AB9-49A6-85F6-744FB426DD31Q37563581-760476E9-76A4-4EEF-A42E-B10A4D348949Q37687958-BBDC8BF2-D114-400C-AF26-688B0E9E129CQ37779322-35BF2F0F-1603-4EBD-B635-99E3CC275FC3Q37833481-7D0765D2-7DDB-451B-B1A7-AE9554E33AA6Q37863680-322DF30D-0CD6-4D4E-9FBC-84CD05380523Q37876951-47A090ED-D68B-4076-8DAC-A8D4DEBA7C86Q38010633-3589240D-034D-4B5B-B470-96857F62C837Q38038696-4B6E4E06-9778-4C01-90B0-439B9A2ECA02Q38041260-7D124F27-C9A1-4650-B5FC-B45881BCE5D4Q38073121-87E90078-796C-41F4-9BE3-2A6877AC5B8BQ38175673-EFB69F62-1B41-45FD-B5F6-74EC6B90D430Q38195885-0BF02070-63E9-4719-9B62-621B11245749Q38210623-26297987-AEF8-4E2F-944D-9E4FD4F1FB78Q38328785-611FBE8B-D296-4705-A290-5D72C8A28A7FQ38533271-EF39CFF5-6CDB-49F0-96B4-AE511A28CC03Q38550117-7B114346-2840-4106-8C0D-895C8530BBC0Q38552310-3203F86F-AAFD-4896-A29C-72FF9F738675Q38640502-ADA34F30-6AC7-4287-B651-35571A5FBEA6Q39015006-6FD68BFA-57F6-443F-A472-FB6CA76FF784Q39297991-264D9843-DC6B-4F8E-9D3C-A0AFE0F68DFAQ39337780-70B7ED9E-A3EE-45C3-990C-BF075DE37F76Q39533979-F4D448E6-E15A-4294-9D9C-9D9A4D291967Q39564761-42420DDB-EEA8-4A85-97C6-8B64A7295CDDQ39610198-C036E0D8-4E4B-46AD-8BEF-339FE7C572D6Q42043813-EF83A507-92D4-464C-8D4A-ED13C430F1D2Q42343473-6E321953-6C3A-4AF2-B303-6B5305164D6C
P2860
Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@en
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@nl
type
label
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@en
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@nl
prefLabel
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@en
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@nl
P2093
P1476
Switch to a sirolimus-based im ...... ed, controlled clinical trial.
@en
P2093
E H Scheuermann
H G Kachel
J Gossmann
R Kaufmann
P304
P356
10.1111/J.1600-6143.2009.02997.X
P407
P577
2010-02-01T00:00:00Z